Medicines campaigners target Abbott over the high price of its Aids drug, Kaletra. Meanwhile an independent but GAVI-funded study shows the roll-out of pneumococcal vaccine it is supporting is cost-effective.
The multinational drug company Abbott is being targeted by health campaigners in a number of countries in a concerted campaign to try to break its monopoly on a valuable Aids drug called Kaletra.
Now Track More Ideas
- PSFK Retail Conference Preview: Ro’s CEO On Democratizing Healthcare Through Telemedicine
- Interview: How Ritual’s Katerina Schneider Brings Transparency To The Women’s Multivitamin
- Interview: Fitness Expert On The Evolution Of The Boutique Gym Experience
- ‘Uber Of Birth Control’ Helps Customers Take At-Home HPV Tests